Global Recognitions in Regenerative Aesthetics: A Journey Shaped by Time
Aphranel's journey in regenerative aesthetics is guided by a long-term commitment to science, innovation, and responsibility.
From pioneering original CaHA microsphere technology in China to achieving international certifications and expanding across global markets, each milestone reflects our belief that meaningful innovation takes time. Through continuous research, physician education, and global collaboration, we remain committed to advancing regenerative aesthetics and building a global brand from China.
2026
EU MDR Certification
Aphranel® obtained European Union MDR certification for its Calcium Hydroxylapatite (CaHA) Microsphere Injectable Facial Filler, becoming the only CaHA product in the Asia-Pacific region currently certified under the EU MDR framework.
2026
Saudi SFDA Registration
Aphranel® obtained Saudi Arabia's highest-risk medical device registration (Class D), supporting the brand's continued expansion across the Middle East
2026
IMCAS Paris
Aphranel® introduced its global brand philosophy, The Poetics of Time, at IMCAS Paris 2026.
2025
Forbes China Beauty 100
Aphranel was selected for Forbes China Beauty 100, recognizing the brand's innovation and growing influence within China's medical aesthetics industry.
2025
China's First NMPA Class III Approval for an Original CaHA Microsphere Injectable Facial Filler
Aphranel® received China's first Class III medical device approval for an original CaHA microsphere injectable facial filler, marking a significant milestone for China-developed regenerative biomaterials.
2025
MD & MDSAP Certification
Moyom Biotechnology obtained EU MD Certification (ISO 13485) and MDSAP certification, establishing a quality management system aligned with the regulatory requirements of the European Union, United States, Canada, Japan, Australia, and Brazil.
